Pluristem to Present Scientific Poster and Corporate Overview at Stem Cell Meeting on the Mesa
October 15 2013 - 3:00AM
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading
developer of placenta-based cell therapies, announced today that
the company will be actively participating in the Stem Cell Meeting
on the Mesa on October 14-16, 2013.
William R. Prather RPh, MD, Pluristem's Senior Vice President of
Corporate Development will deliver a corporate presentation on
Pluristem on October 14th at 5 pm PT. Additionally, Dr. Prather
will be presenting a scientific poster on October 16th titled,
"PLacental eXpanded (PLX) Cell Treatment Ameliorates Toll-like
Receptor-Mediated Preeclampsia in Mice".
The 2013 Stem Cell Meeting on the Mesa is a three-day conference
aimed at bringing together senior members of the regenerative
medicine industry with the scientific research community to advance
stem cell science into cures. The meeting features a nationally
recognized Scientific Symposium, attended by leading scientists and
researchers, in conjunction with the industry's premier annual
Regen Med Partnering Forum. Combined, these meetings attract over
800 attendees from around the globe, fostering key partnerships
through one-on-one meetings while also highlighting clinical and
commercial progress in the field.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of
placenta-based cell therapies. The Company's patented PLX
(PLacental eXpanded) cells are a drug delivery platform that
releases a cocktail of therapeutic proteins in response to a host
of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental
technology and are an "off-the-shelf" product that requires no
tissue matching prior to administration.
Pluristem has a strong intellectual property position,
company-owned GMP certified manufacturing and research facilities,
strategic relationships with major research institutions and a
seasoned management team. For more information visit
www.pluristem.com, the content of which is not part of this press
release.
The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and federal securities
laws. These forward-looking statements and their implications are
based on the current expectations of the management of Pluristem
only, and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those
described in the forward-looking statements. The following factors,
among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in
technology and market requirements; we may encounter delays or
obstacles in launching and/or successfully completing our clinical
trials; our products may not be approved by regulatory agencies,
our technology may not be validated as we progress further and our
methods may not be accepted by the scientific community; we may be
unable to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up
being more expensive than we anticipate; results in the laboratory
may not translate to equally good results in real surgical
settings; results of preclinical studies may not correlate with the
results of human clinical trials; our patents may not be
sufficient; our products may harm recipients; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; loss of market share and
pressure on pricing resulting from competition, which could cause
the actual results or performance of Pluristem to differ materially
from those contemplated in such forward-looking statements. Except
as otherwise required by law, Pluristem undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time
with the Securities and Exchange Commission.
CONTACT: Pluristem Therapeutics Inc.:
William Prather R.Ph., M.D. Sr. VP Corporate Development
1-303-883-4954
William.PratherMD@pluristem.com
Daya Lettvin
Investor & Media Relations Director
+972-54-674-5580
daya@pluristem.com
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Jul 2023 to Jul 2024